Robotti Robert Trimmed Cavco Inds Del (CVCO) Stake; Barclays Plc Has Decreased Its Sage Therapeutics (Put) (SAGE) Stake

February 19, 2018 - By Hazel Jackson

Robotti Robert decreased Cavco Inds Inc Del (CVCO) stake by 16.92% reported in 2017Q3 SEC filing. Robotti Robert sold 29,230 shares as Cavco Inds Inc Del (CVCO)’s stock declined 2.45%. The Robotti Robert holds 143,493 shares with $21.17 million value, down from 172,723 last quarter. Cavco Inds Inc Del now has $1.53 billion valuation. The stock increased 0.36% or $0.6 during the last trading session, reaching $169.05. About 47,497 shares traded or 6.52% up from the average. Cavco Industries, Inc. (NASDAQ:CVCO) has risen 19.38% since February 19, 2017 and is uptrending. It has outperformed by 2.68% the S&P500.




Barclays Plc decreased Sage Therapeutics Inc (Put) (SAGE) stake by 86.42% reported in 2017Q3 SEC filing. Barclays Plc sold 371,600 shares as Sage Therapeutics Inc (Put) (SAGE)’s stock rose 0.86%. The Barclays Plc holds 58,400 shares with $3.64M value, down from 430,000 last quarter. Sage Therapeutics Inc (Put) now has $7.39B valuation. The stock decreased 0.75% or $1.23 during the last trading session, reaching $162.37. About 467,420 shares traded. Sage Therapeutics, Inc. (NASDAQ:SAGE) has risen 116.45% since February 19, 2017 and is uptrending. It has outperformed by 99.75% the S&P500.

Since December 14, 2017, it had 0 buys, and 2 insider sales for $17.36 million activity. Robichaud Albert also sold $9.57 million worth of Sage Therapeutics, Inc. (NASDAQ:SAGE) shares. 44,000 shares valued at $7.80M were sold by Kanes Stephen on Wednesday, January 10.

Barclays Plc increased Macys Inc (Put) (NYSE:M) stake by 424,400 shares to 541,100 valued at $11.81M in 2017Q3. It also upped Williams Sonoma Inc (Call) (NYSE:WSM) stake by 27,400 shares and now owns 79,500 shares. Tata Mtrs Ltd (Put) (NYSE:TTM) was raised too.

Investors sentiment increased to 1.21 in 2017 Q3. Its up 0.23, from 0.98 in 2017Q2. It increased, as 33 investors sold SAGE shares while 43 reduced holdings. 28 funds opened positions while 64 raised stakes. 38.55 million shares or 3.62% more from 37.20 million shares in 2017Q2 were reported. Federated Investors Pa accumulated 752,557 shares. Moreover, Victory Cap has 0.05% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE). Us Bancorp De, a Minnesota-based fund reported 68 shares. 4,815 were accumulated by Tudor Invest Corporation Et Al. Moreover, Alyeska Group Lp has 0.06% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE). Fiera Capital Corp has 0.01% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 41,649 shares. 6 were reported by Cwm Ltd Liability Corporation. Principal Financial Grp Inc invested in 5,363 shares. Art Advisors Lc accumulated 33,800 shares or 0.11% of the stock. Lord Abbett And Co has 0.05% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE). Jabre Cap Ptnrs Sa has 6,000 shares for 0.07% of their portfolio. Citigroup holds 0% or 39,026 shares in its portfolio. Bamco Incorporated New York reported 93,458 shares stake. Harbourvest Prns Ltd Llc holds 11,319 shares. 77,977 are held by Credit Suisse Ag.

Among 17 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 15 have Buy rating, 0 Sell and 2 Hold. Therefore 88% are positive. SAGE Therapeutics had 52 analyst reports since September 3, 2015 according to SRatingsIntel. The rating was maintained by Cowen & Co on Thursday, November 9 with “Buy”. The rating was maintained by Cowen & Co on Thursday, August 3 with “Buy”. The company was upgraded on Thursday, December 7 by Chardan Capital Markets. The firm has “Buy” rating by Cowen & Co given on Tuesday, September 12. The firm has “Neutral” rating by Goldman Sachs given on Wednesday, March 30. The stock has “Strong Buy” rating by Raymond James on Wednesday, December 14. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) earned “Buy” rating by SunTrust on Thursday, October 19. H.C. Wainwright initiated the shares of SAGE in report on Thursday, June 23 with “Buy” rating. Leerink Swann maintained Sage Therapeutics, Inc. (NASDAQ:SAGE) on Tuesday, September 12 with “Buy” rating. The firm has “Hold” rating given on Friday, August 4 by H.C. Wainwright.

Analysts await Sage Therapeutics, Inc. (NASDAQ:SAGE) to report earnings on February, 22. They expect $-2.04 EPS, down 36.00% or $0.54 from last year’s $-1.5 per share. After $-1.97 actual EPS reported by Sage Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 3.55% negative EPS growth.

Since September 19, 2017, it had 0 buys, and 2 insider sales for $840,904 activity. $430,861 worth of Cavco Industries, Inc. (NASDAQ:CVCO) was sold by Boor William C. The insider Greenblatt David A. sold $410,043.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.